WallStreetZenWallStreetZen

NASDAQ: SNSE
Sensei Biotherapeutics Inc Stock

$1.05-0.04 (-3.67%)
Updated Mar 28, 2024
SNSE Price
$1.05
Fair Value Price
$1.39
Market Cap
$26.32M
52 Week Low
$0.51
52 Week High
$1.93
P/E
-0.86x
P/B
0.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.10M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$32M
Beta
1.02
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SNSE Overview

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNSE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SNSE ($1.05) is undervalued by 24.2% relative to our estimate of its Fair Value price of $1.39 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SNSE ($1.05) is significantly undervalued by 24.2% relative to our estimate of its Fair Value price of $1.39 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SNSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNSE due diligence checks available for Premium users.

Be the first to know about important SNSE news, forecast changes, insider trades & much more!

SNSE News

Valuation

SNSE fair value

Fair Value of SNSE stock based on Discounted Cash Flow (DCF)
Price
$1.05
Fair Value
$1.39
Undervalued by
24.20%
SNSE ($1.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNSE ($1.05) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SNSE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.86x
Industry
14.26x
Market
44.51x

SNSE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.41x
Industry
6.21x
SNSE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SNSE's financial health

Profit margin

Revenue
$0.0
Net Income
-$7.4M
Profit Margin
0%
SNSE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$74.4M
Liabilities
$9.5M
Debt to equity
0.15
SNSE's short-term assets ($67.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNSE's short-term assets ($67.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNSE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNSE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.2M
Investing
$8.3M
Financing
-$431.0k
SNSE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SNSE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SNSE$26.32M-3.67%-0.86x0.41x
ORGS$26.20M-3.29%0.91x2.11x
APTO$26.09M+10.67%-0.22x-8.99x
BIOR$26.07M-5.98%-0.11x-0.22x
ONCT$26.64M+9.76%-0.67x0.89x

Sensei Biotherapeutics Stock FAQ

What is Sensei Biotherapeutics's quote symbol?

(NASDAQ: SNSE) Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol SNSE. Sensei Biotherapeutics stock quotes can also be displayed as NASDAQ: SNSE.

If you're new to stock investing, here's how to buy Sensei Biotherapeutics stock.

What is the 52 week high and low for Sensei Biotherapeutics (NASDAQ: SNSE)?

(NASDAQ: SNSE) Sensei Biotherapeutics's 52-week high was $1.93, and its 52-week low was $0.51. It is currently -45.48% from its 52-week high and 105.88% from its 52-week low.

How much is Sensei Biotherapeutics stock worth today?

(NASDAQ: SNSE) Sensei Biotherapeutics currently has 25,070,980 outstanding shares. With Sensei Biotherapeutics stock trading at $1.05 per share, the total value of Sensei Biotherapeutics stock (market capitalization) is $26.32M.

Sensei Biotherapeutics stock was originally listed at a price of $22.75 in Feb 8, 2021. If you had invested in Sensei Biotherapeutics stock at $22.75, your return over the last 3 years would have been -95.38%, for an annualized return of -64.13% (not including any dividends or dividend reinvestments).

How much is Sensei Biotherapeutics's stock price per share?

(NASDAQ: SNSE) Sensei Biotherapeutics stock price per share is $1.05 today (as of Mar 28, 2024).

What is Sensei Biotherapeutics's Market Cap?

(NASDAQ: SNSE) Sensei Biotherapeutics's market cap is $26.32M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sensei Biotherapeutics's market cap is calculated by multiplying SNSE's current stock price of $1.05 by SNSE's total outstanding shares of 25,070,980.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.